Why Medication Alone Isn’t Enough

Medication can save lives. SSRIs can lift the weight of depression. Anxiolytics can stop a panic attack in its tracks. Beta-blockers can calm a racing heart before a presentation. This is not an argument against medication.

But stabilization is not resolution^[1]. Medication addresses the neurochemical output of a pathological neural network. It does not address the network itself.

What Medication Does

SSRIs increase serotonin availability in synaptic clefts, improving mood regulation. Benzodiazepines enhance GABA activity, reducing anxiety. Beta-blockers block adrenaline receptors, dampening physiological arousal.

These are valuable interventions. They reduce suffering, improve functioning, and can create the stability necessary for other therapeutic work. Research has documented their efficacy across multiple conditions.

What Medication Does Not Do

Medication does not locate the pathological neural network that generates the symptoms. It does not collapse the stored fear charge. It does not modify the synaptic architecture that maintains the pattern.

This is why symptoms often return when medication is discontinued. The network was suppressed, not resolved. When the pharmacological suppression is removed, the network reactivates.

The Structural Complement

The Efremov Method® teaches a structural skill for locating and collapsing the neural network that generates emotional and psychosomatic symptoms. It is not a replacement for medication. People who are currently medicated should consult their prescriber before making any changes.

For some, medication provides the stability needed to engage with structural work. For others, structural work reduces the need for ongoing medication. The appropriate combination is individual.

Stabilization vs. Resolution: Two Different Operations

Medication can be a valuable tool. SSRIs increase available serotonin. Benzodiazepines enhance GABA activity. Beta-blockers reduce physiological arousal. For many people, these medications provide meaningful relief from symptoms that were otherwise overwhelming.

But medication addresses the neurochemical output of a fear-based neural network, not the network itself. When you take an SSRI, you modulate the serotonin imbalance produced by the pathological network. When you take a benzodiazepine, you enhance the inhibitory neurotransmitter that the network’s chronic activation has depleted. These are stabilization operations — they manage the chemical fallout of the network’s activity.

Resolution — collapsing the network that produces the symptoms — is a different operation entirely. This is why many people find that when they discontinue medication, the symptoms return. The generator was never addressed; only its outputs were buffered.

The Neurochemical Cascade: What Medication Actually Targets

Research published in Clinical Psychopharmacology and Neuroscience has documented the neurochemical cascade produced by pathological neural networks^[2]: disrupted serotonin and dopamine metabolism, chronic cortisol elevation, pro-inflammatory cytokine release, and altered gut microbiota composition. Medication can modulate each of these parameters individually.

But the cascade is not the disease. It is the consequence of a network that fires chronically. Modulating the cascade while the network continues to fire is like mopping the floor while the faucet is still running — helpful in the short term, but not a solution.

The Structural Complement

The Efremov Method® is not anti-medication. Medication can provide the stability needed to engage with deeper structural work. The method addresses a different level of the problem: the pathological neural network itself. When the network’s charge is collapsed, the neurochemical cascade it produced ceases at the source.

For some people, this may mean that the conditions which originally necessitated medication are no longer present. For others, medication may continue to serve a useful role. These are decisions to be made with healthcare providers, not with educational frameworks.

The Rebound Effect: What Happens When Medication Stops

One of the most significant clinical observations in psychopharmacology is the rebound effect: when medication is discontinued, symptoms frequently return — sometimes with greater intensity than before treatment. This occurs because the pathological neural network that generates the symptoms was never addressed; the medication was modulating the network’s chemical outputs while the network itself continued to operate.

Additionally, neuroadaptation occurs during medication use: the brain adjusts its own neurotransmitter production and receptor sensitivity in response to the medication. When the medication is removed, the brain must readjust — and during this readjustment period, the unaddressed neural network’s outputs may be amplified by the withdrawal of the chemical buffer that was managing them.

The Role of the Gut-Brain Axis

Research published in Clinical Psychopharmacology and Neuroscience has documented that cognitive behavioral therapy can alter the gut-brain-microbiome axis^[3], producing changes in gut bacteria composition that correlate with symptom improvement. Specifically, CBT was shown to increase serotonin levels in the gut, increase beneficial Clostridiales bacteria, and decrease Bacteroides — changes associated with reduced IBS symptoms and improved emotional regulation.

This finding is remarkable because it demonstrates that psychological intervention can produce measurable biological changes at the gut microbiome level — supporting the principle that addressing the generating mechanism (in this case, through structured cognitive work) produces changes downstream that medication targets chemically. The implication is that structural approaches operating at the neural network level may produce even more fundamental changes, as they target the generator itself rather than its cognitive manifestations.